comprehensive -WSS

comprehensive

author：focus 2025-09-10 08:40:46 - browse：74877

Blood samples — Marion Berard/AFP/GettyImages

With the advent of disease-modifying Alzheimer’s drugs, everyone in the world of Alzheimer’s diagnostics is bracing for the crush.

Based on their ability to slow cognitive decline, the Eisai/Biogen drug Leqembi won full approval from the FDA this month, and donanemab by Eli Lilly could be approved by year end. Clinicians now have to decide which patients are most suitable for treatment, which means better Alzheimer’s tests need to be developed.

“There’s going to be capacity issues because there’s just not enough neurologists in the world to treat this pool of patients with Alzheimer’s disease at the moment,” said Mark Stearman, a senior international product manager at Roche focusing on Alzheimer’s diagnostics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： EU climate chief is concerned over the expansion of the coal industry in China

WSS

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Why Novartis is going to walk from its acquisition of MorphoSys

Cano Health’s bankruptcy is a warning for Medicare Advantage

A timeline of the missing Titanic tourist submersible

US judge blocks portions of new Florida elections law

The CDC's new social media misinformation war

explore

comprehensive

knowledge

Medical leaders decry Supreme Court decision on affirmative action

4 dead, 2 in stable condition in Philadelphia shooting: Police

United colonoscopy coverage change 'may cost lives,' doctors say

US recommends Americans reconsider traveling to China due to arbitrary law enforcement, exit bans

Walensky prepares to leave CDC — and Congress — behind

Updated Covid vaccine has 54% effectiveness, new study suggests

23andMe had bad news about my health. I wish a person had delivered it

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Russians and Belarusians back at Wimbledon as war in Ukraine continues

knowledge

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Bernie brings in new pharma CEOs to talk drug prices

PlayStation controller and acoustic messaging: How the missing Titanic tourist sub works

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

leisure time

focus

focus

hotspot